Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Target hemoglobin in patients with renal failure.

K U Eckardt1

  • 1Department of Nephrology and Medical Intensive Care, Charité, Campus Virchow-Klinikum, Berlin, Germany. kai-uwe.eckardt@charite.de

Nephron
|September 11, 2001
PubMed
Summary

Recombinant erythropoietin (EPO) treats renal anemia, but target hemoglobin levels remain debated. While improving quality of life, normalizing hemoglobin may pose risks in advanced cardiac disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hemophagocytic lymphohistiocytosis and thrombotic microangiopathy after parvovirus B19 infection and renal transplantation: a case report.

BMC nephrology·2021
Same author

Effects of anemia and uremia and a combination of both on cardiovascular structures.

Kidney & blood pressure research·2010
Same author

The potential of erythropoietin and related strategies to stimulate erythropoiesis.

Current opinion in investigational drugs (London, England : 2000)·2002
Same author

Anaemia in end-stage renal disease: pathophysiological considerations.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2001
Same author

After 15 years of success--perspectives of erythropoietin therapy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2001
Same author

Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.

Cancer research·2001

Area of Science:

  • Nephrology
  • Cardiology
  • Hematology

Background:

  • Recombinant erythropoietin (EPO) has been used for renal anemia for 15 years.
  • Optimal hemoglobin targets for treatment remain controversial.
  • Anemia is linked to left-ventricular hypertrophy progression and mortality.

Observation:

  • Partial anemia correction improves quality of life.
  • Normalization of hemoglobin may further enhance well-being.
  • Evidence suggests anemia correction can improve patient prognosis.

Findings:

  • Patients with advanced cardiac disease may not benefit from normalized hemoglobin and could be harmed.
  • Complete correction may prevent ventricular dilatation in less advanced cardiac disease.
  • Current guidelines set a lower hemoglobin target of 11 g/dl.

Implications:

  • Early anemia correction is being studied in predialysis patients.
  • Many patients do not achieve guideline-recommended hemoglobin levels.
  • Significant numbers of patients remain below target hemoglobin, indicating treatment gaps.

Related Experiment Videos